Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.4 - $4.27 $6,730 - $71,842
-16,825 Reduced 2.9%
563,488 $223,000
Q2 2022

Aug 12, 2022

BUY
$0.56 - $1.29 $5,580 - $12,856
9,966 Added 1.75%
580,313 $327,000
Q1 2022

May 12, 2022

SELL
$0.72 - $1.86 $3,726 - $9,625
-5,175 Reduced 0.9%
570,347 $638,000
Q4 2021

Feb 10, 2022

SELL
$1.3 - $3.17 $422,640 - $1.03 Million
-325,108 Reduced 36.1%
575,522 $840,000
Q3 2021

Nov 09, 2021

BUY
$2.91 - $4.5 $52,551 - $81,265
18,059 Added 2.05%
900,630 $2.7 Million
Q2 2021

Aug 11, 2021

BUY
$4.15 - $6.3 $3.66 Million - $5.56 Million
882,571 New
882,571 $4.09 Million

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $14M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.